![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus
Core Inhibitor: Final Results of a Phase 1 Study in Healthy Adult Subjects
|
|
|
EASL 2020 Aug 27-29 virtual
Reported by Jules Levin
Kajal Larson1, Alaa Ahmad1, Eoin Coakley1, Ty McClure1, Jingwen Chai1, Daniel Dickerson2, and Nathalie Adda1
1Enanta Pharmaceuticals, Inc., Watertown, Massachusetts, USA; 2PRA Health Sciences -Lenexa, Lenexa, Kansas, USA
![0927201](../images/092720/092720-5/0927201.gif)
![0927202](../images/092720/092720-5/0927202.gif)
![0927203](../images/092720/092720-5/0927203.gif)
![0927204](../images/092720/092720-5/0927204.gif)
![0927205](../images/092720/092720-5/0927205.gif)
![0927206](../images/092720/092720-5/0927206.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|